Multiplexed Liquid Biopsy and Tumor Imaging Using Surface-Enhanced Raman Scattering

Dell’Olio, Francesco

doi:10.3390/bios11110449

Cited by 9 publications

(9 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 140 ] Despite this, one of the greater benefits of using SERS for quantitative CTC detection is that the technique does not necessarily require an enrichment step, as required by other platforms for CTC detection from peripheral blood. [ 141 ] SERS can also characterize single tumor cells as each molecule has a unique Raman spectrum fingerprint. [ 142 ] The main advantages of SERS technology for CTC detection are high detection sensitivity and specificity, with low false positive and false negative rates.…”

Section: Micro and Nano Biosensors For Liquid Biopsymentioning

confidence: 99%

Toward Personalized Nanomedicine: The Critical Evaluation of Micro and Nanodevices for Cancer Biomarker Analysis in Liquid Biopsy

Clack

Soda

Kasetsirikul

et al. 2023

Small

View full text Add to dashboard Cite

from circulating biomarkers (CBs). CBs may be found in several minimally invasive bodily fluids including (but not limited to) blood, saliva, urine, pleural effusions, stool, and cerebrospinal fluid. CBs may include circulating tumor cells (CTCs), circulating tumor RNA/DNA (ctRNA/ctDNA), microRNAs (miRNAs), long non-coding RNAs (lncRNAs), proteins, exosomes, autoantibodies, all of which, are known for their diagnostic and prognostic potential. [1] Currently, clinicians and centralized hospitals practice tissue biopsy for diagnosis and characterization of the heterogeneity of the solid tumor which is crucial for personalized medicine. [1a] Despite the many decades of clinical practice, tissue-based biopsies are subject to sampling bias, suffer from the issue of low repeatability, and cause immense pain in patients as the process is invasive. One of the major concerns of biopsies, often ignored, is the entrance of tumor cells into the systemic circulation during the tissue-sampling process, leading to tumor metastasis. [2] To overcome these issues, the detection of CBs through liquid biopsy has shown promise as a potential replacement due to the rapid and semi or non-invasive sampling process and the repeated analysis of samples during therapeutic interventions aid in decision-making about a particular patient's progress.Due to the advancement of highly specific sequencing and gene amplification technologies, liquid biopsies can access more relevant cancer biomarkers, providing a much-needed alternative to tissue-based biopsy. [1b] These recent advances have led to the development of many miniaturized/ portable platforms. The clinical potential of these micro and nano devices is rapidly growing, but they face many challenges before transitioning to point-of-care (POC) platforms that are sensitive, rapid, and accurate, as discussed herein.Previously, our group [3] provided a critical review of circulating tumor DNA (ctDNA) and liquid biopsy opportunities, challenges, and recent advances in detection technologies. The review examines the potential of ctDNA as a marker in liquid biopsy, as well as the detection methods, challenges, and considerations. We further [1b] provided a comprehensive review of advanced liquid biopsy technologies for CBs detection. Others Liquid biopsy for the analysis of circulating cancer biomarkers (CBs) is a major advancement toward the early detection of cancer. In comparison to tissue biopsy techniques, liquid biopsy is relatively painless, offering multiple sampling opportunities across easily accessible bodily fluids such as blood, urine, and saliva. Liquid biopsy is also relatively inexpensive and simple, avoiding the requirement for specialized laboratory equipment or trained medical staff. Major advances in the field of liquid biopsy are attributed largely to developments in nanotechnology and microfabrication that enables the creation of highly precise chip-based platforms. These devices can overcome detection limitations of an individual biomarker by detecting multiple markers ...

show abstract

Section: Micro and Nano Biosensors For Liquid Biopsymentioning

confidence: 99%

Toward Personalized Nanomedicine: The Critical Evaluation of Micro and Nanodevices for Cancer Biomarker Analysis in Liquid Biopsy

Clack

Soda

Kasetsirikul

et al. 2023

Small

View full text Add to dashboard Cite

show abstract

“…Elastic and inelastic scattering are examples of scattering events that can happen when photons interact with materials ( Dell'Olio, 2021a ). Inelastic light scattering of molecules was first observed by the Indian scientist Raman in 1928 and later called Raman scattering.…”

Section: Raman Spectroscopymentioning

confidence: 99%

Advances in the application of Raman spectroscopy in haematological tumours

Liang

Shi

Wang

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Hematologic malignancies are a diverse collection of cancers that affect the blood, bone marrow, and organs. They have a very unpredictable prognosis and recur after treatment. Leukemia, lymphoma, and myeloma are the most prevalent symptoms. Despite advancements in chemotherapy and supportive care, the incidence rate and mortality of patients with hematological malignancies remain high. Additionally, there are issues with the clinical diagnosis because several hematological malignancies lack defined, systematic diagnostic criteria. This work provided an overview of the fundamentals, benefits, and limitations of Raman spectroscopy and its use in hematological cancers. The alterations of trace substances can be recognized using Raman spectroscopy. High sensitivity, non-destructive, quick, real-time, and other attributes define it. Clinicians must promptly identify disorders and keep track of analytes in biological fluids. For instance, surface-enhanced Raman spectroscopy is employed in diagnosing gene mutations in myelodysplastic syndromes due to its high sensitivity and multiple detection benefits. Serum indicators for multiple myeloma have been routinely used for detection. The simultaneous observation of DNA strand modifications and the production of new molecular bonds by tip-enhanced Raman spectroscopy is of tremendous significance for diagnosing lymphoma and multiple myeloma with unidentified diagnostic criteria.

show abstract

“…Liquid biopsy is the in vitro detection of disease biomarkers in body fluids (blood, cerebrospinal fluid, urine, sputum, and ascites) [108], which can be useful not only for identifying diseases, but also for identifying drug resistance mechanisms, stratifying patients, and predicting treatment efficacy. Many different molecules have been identified in body fluids, including disease-related proteins, circulating tumour cells, cell-free tumour DNA, cancer-derived exosomes, mRNA, and cell-free microRNAs [108].…”

Section: Liquid Biopsymentioning

confidence: 99%

Section: Liquid Biopsymentioning

confidence: 99%

How Surface-Enhanced Raman Spectroscopy Could Contribute to Medical Diagnoses

et al. 2022

View full text Add to dashboard Cite

In the last decade, there has been a rapid increase in the number of surface-enhanced Raman scattering (SERS) spectroscopy applications in medical research. In this article we review some recent, and in our opinion, most interesting and promising applications of SERS spectroscopy in medical diagnostics, including those that permit multiplexing within the range important for clinical samples. We focus on the SERS-based detection of markers of various diseases (or those whose presence significantly increases the chance of developing a given disease), and on drug monitoring. We present selected examples of the SERS detection of particular fragments of DNA or RNA, or of bacteria, viruses, and disease-related proteins. We also describe a very promising and elegant ‘lab-on-chip’ approach used to carry out practical SERS measurements via a pad whose action is similar to that of a pregnancy test. The fundamental theoretical background of SERS spectroscopy, which should allow a better understanding of the operation of the sensors described, is also briefly outlined. We hope that this review article will be useful for researchers planning to enter this fascinating field.

show abstract

Multiplexed Liquid Biopsy and Tumor Imaging Using Surface-Enhanced Raman Scattering

Cited by 9 publications

References 90 publications

Toward Personalized Nanomedicine: The Critical Evaluation of Micro and Nanodevices for Cancer Biomarker Analysis in Liquid Biopsy

Toward Personalized Nanomedicine: The Critical Evaluation of Micro and Nanodevices for Cancer Biomarker Analysis in Liquid Biopsy

Advances in the application of Raman spectroscopy in haematological tumours

How Surface-Enhanced Raman Spectroscopy Could Contribute to Medical Diagnoses

Contact Info

Product

Resources

About